- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Bio-Thera Seeks to Enter Brazilian Market for Bevacizumab
Building on regulatory submissions elsewhere, the company is looking to gain approval for bevacizumab candidate BAT1706 in Brazil.
A Guangzhou, China, company that has submitted a bevacizumab biosimilar candidate for regulatory approval in China and Europe is moving ahead with a similar filing in Brazil.
Bio-Thera Solutions has developed BAT1706 and recently completed a phase 3 comparative clinical study demonstrating equivalence to the reference product (Avastin) for efficacy, safety, pharmacokinetics, and immunogenicity in patients with advanced nonsquamous non–small cell lung cancer who also received chemotherapy.
The company now has contracted for Biomm SA to submit the regulatory paperwork for BAT1706 in Brazil and handle the product distribution in that market. “This partnership will leverage Biomm’s strong local presence, sales, and marketing capabilities in Brazil,” Bio-Thera said in a statement that also explained that it would handle the product manufacturing side of the partnership, utilizing its biopharmaceutical plant in Guangzhou.
“This partnership is the first to expand Bio-Thera’s presence into Brazil, an important pharmaceutical market for biosimilars and innovative drugs,” Shengfeng Li, CEO of Bio-Thera, said in the statement.
BAT1706 is intended for the treatment of patients with metastatic colorectal cancer; metastatic or locally recurrent breast cancer; locally advanced, metastatic, or recurrent non–small cell lung cancer; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Heraldo Marchezini, CEO of Biomm, said his company was eager to expand its activities in the oncology biologics space. "Biomm is committed to expanding its portfolio in biotechnology with a long-term vision, especially in oncology where is critical to expand the access to modern treatments.”
In September 2020, Bio-Thera announced distribution partners for the marketing of BAT1706 in China and Russia. In January, Bio-Thera launched the first adalimumab biosimilar (Qletli) in China.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
